162 related articles for article (PubMed ID: 18311685)
1. Tiagabine treatment is associated with neurochemical, immune and behavioural alterations in the olfactory bulbectomized rat model of depression.
Pistovcakova J; Dostalek M; Sulcova A; Jezova D
Pharmacopsychiatry; 2008 Mar; 41(2):54-9. PubMed ID: 18311685
[TBL] [Abstract][Full Text] [Related]
2. The effects of central administration of neuropeptide Y on behavior, neurotransmitter, and immune functions in the olfactory bulbectomized rat model of depression.
Song C; Earley B; Leonard BE
Brain Behav Immun; 1996 Mar; 10(1):1-16. PubMed ID: 8735565
[TBL] [Abstract][Full Text] [Related]
3. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Dhir A; Akula KK; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
[TBL] [Abstract][Full Text] [Related]
4. Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti-depressant tianeptine.
Breivik T; Gundersen Y; Myhrer T; Fonnum F; Osmundsen H; Murison R; Gjermo P; von Hörsten S; Opstad PK
J Clin Periodontol; 2006 Jul; 33(7):469-77. PubMed ID: 16820034
[TBL] [Abstract][Full Text] [Related]
5. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats.
Song C; Horrobin DF; Leonard BE
Pharmacopsychiatry; 2006 May; 39(3):88-99. PubMed ID: 16721697
[TBL] [Abstract][Full Text] [Related]
6. Olfactory bulbectomy in mice leads to increased BDNF levels and decreased serotonin turnover in depression-related brain areas.
Hellweg R; Zueger M; Fink K; Hörtnagl H; Gass P
Neurobiol Dis; 2007 Jan; 25(1):1-7. PubMed ID: 16990008
[TBL] [Abstract][Full Text] [Related]
7. The olfactory bulbectomized rat as a model of depression: an update.
Kelly JP; Wrynn AS; Leonard BE
Pharmacol Ther; 1997; 74(3):299-316. PubMed ID: 9352586
[TBL] [Abstract][Full Text] [Related]
8. The olfactory bulbectomised rat as a model of depression.
Song C; Leonard BE
Neurosci Biobehav Rev; 2005; 29(4-5):627-47. PubMed ID: 15925697
[TBL] [Abstract][Full Text] [Related]
9. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
Iijima M; Chaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
[TBL] [Abstract][Full Text] [Related]
10. Behavioural and neurochemical features of olfactory bulbectomized rats resembling depression with comorbid anxiety.
Wang D; Noda Y; Tsunekawa H; Zhou Y; Miyazaki M; Senzaki K; Nabeshima T
Behav Brain Res; 2007 Mar; 178(2):262-73. PubMed ID: 17261334
[TBL] [Abstract][Full Text] [Related]
11. Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites.
Sato H; Skelin I; Debonnel G; Diksic M
Brain Res Bull; 2008 Mar; 75(5):545-55. PubMed ID: 18355630
[TBL] [Abstract][Full Text] [Related]
12. Behavioural and neurochemical evaluation of Perment an herbal formulation in chronic unpredictable mild stress induced depressive model.
Ramanathan M; Balaji B; Justin A
Indian J Exp Biol; 2011 Apr; 49(4):269-75. PubMed ID: 21614890
[TBL] [Abstract][Full Text] [Related]
13. Effects of tiagabine, a gamma-aminobutyric acid re-uptake inhibitor, on normal rat bladder function.
Pehrson R; Andersson KE
J Urol; 2002 May; 167(5):2241-6. PubMed ID: 11956486
[TBL] [Abstract][Full Text] [Related]
14. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression.
Myint AM; Steinbusch HW; Goeghegan L; Luchtman D; Kim YK; Leonard BE
Neuroimmunomodulation; 2007; 14(2):65-71. PubMed ID: 17713352
[TBL] [Abstract][Full Text] [Related]
15. Olfactory bulbectomy induces rapid and stable changes in basal and stress-induced locomotor activity, heart rate and body temperature responses in the home cage.
Vinkers CH; Breuer ME; Westphal KG; Korte SM; Oosting RS; Olivier B; Groenink L
Neuroscience; 2009 Mar; 159(1):39-46. PubMed ID: 19136045
[TBL] [Abstract][Full Text] [Related]
16. Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production in response to an in vivo challenge with lipopolysaccharide: effect of chronic desipramine treatment.
Connor TJ; Harkin A; Kelly JP; Leonard BE
Neuroimmunomodulation; 2000; 7(1):27-35. PubMed ID: 10601816
[TBL] [Abstract][Full Text] [Related]
17. The olfactory bulbectomized rat as a model of depression.
Leonard BE
Pol J Pharmacol Pharm; 1984; 36(5):561-9. PubMed ID: 6099892
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy.
Jarosik J; Legutko B; Unsicker K; von Bohlen Und Halbach O
Exp Neurol; 2007 Mar; 204(1):20-8. PubMed ID: 17059819
[TBL] [Abstract][Full Text] [Related]
19. Locomotor sensitization to cocaine in rats with olfactory bulbectomy.
Chambers RA; Sheehan T; Taylor JR
Synapse; 2004 Jun; 52(3):167-75. PubMed ID: 15065217
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model.
Saitoh A; Yamada M; Yamada M; Takahashi K; Yamaguchi K; Murasawa H; Nakatani A; Tatsumi Y; Hirose N; Kamei J
Brain Res; 2008 May; 1208():160-9. PubMed ID: 18381208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
